Page last updated: 2024-11-03

opc 12759 and Prostatic Hyperplasia

opc 12759 has been researched along with Prostatic Hyperplasia in 1 studies

rebamipide: structure in first source; RN refers to (+-)-isomer; inhibits gastric xanthine oxidase

Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.

Research Excerpts

ExcerptRelevanceReference
"A large proportion of benign prostatic hyperplasia (BPH) patients suffer from lower urinary tract symptoms after surgery due to the presence of prostatic urothelium wounds."1.56Rebamipide-loaded chitosan nanoparticles accelerate prostatic wound healing by inhibiting M1 macrophage-mediated inflammation via the NF-κB signaling pathway. ( Cui, X; Deng, Z; Han, B; Jiang, C; Jing, Y; Li, W; Shi, F; Sun, M; Xia, S; Xu, Z; Zhang, W; Zhou, Z, 2020)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Sun, M1
Deng, Z1
Shi, F1
Zhou, Z1
Jiang, C1
Xu, Z1
Cui, X1
Li, W1
Jing, Y1
Han, B1
Zhang, W1
Xia, S1

Other Studies

1 other study available for opc 12759 and Prostatic Hyperplasia

ArticleYear
Rebamipide-loaded chitosan nanoparticles accelerate prostatic wound healing by inhibiting M1 macrophage-mediated inflammation via the NF-κB signaling pathway.
    Biomaterials science, 2020, Feb-07, Volume: 8, Issue:3

    Topics: Alanine; Animals; Cell Proliferation; Chitosan; Dogs; Drug Compounding; Humans; Macrophages; Male; N

2020